FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113257039> ?p ?o ?g. }

• W2113257039 endingPage "2029" @default.
• W2113257039 startingPage "2024" @default.
• W2113257039 abstract "Background: Vancomycin alternatives, including clindamycin, have in vitro activity against current strains of methicillin-resistant Staphylococcus aureus (MRSA), but clinical evidence of their effectiveness is needed. Objective: The aim of this work was to compare health outcomes for hospitalized adult patients treated with vancomycin and clindamycin for skin and soft- tissue infections caused by MRSA. Methods: This was a retrospective chart review of patients admitted to University Hospital (San Antonio, Texas) with culture-proven MRSA skin or soft-tissue infections from July 1, 2006, to December 31, 2006. Patients were subdivided into groups according to antibiotics received on the first day of hospital admission. The primary outcome was composite failure, which was defined as having an additional positive MRSA culture 5 to 90 days after initial culture or requiring an additional intervention (eg, new course of antibiotics or additional incision and drainage within 90 days after initiation of therapy). Descriptive statistics were used to characterize each group; χ2, Fisher exact, and Wilcoxon rank sum tests were used to assess differences between the vancomycin and clindamycin groups. Results: Ninety-one patients received vancomycin (n = 40) or clindamycin (n = 51) for a MRSA skin infection. Most vancomycin-treated patients received 1 g IV q12h (92.5% [37/40]), whereas most clindamycintreated patients received 600 mg IV q8h (51.0% [26/51]) or 900 mg IV q8h (27.5% [14/51]). The vancomycin and clindamycin groups had no significant differences with regard to median age (38 vs 37 years, respectively), male sex (62.5% [25/40] vs 74.5% [38/51]), or Hispanic ethnicity (77.5% [31/40] vs 78.4% [40/51]). All MRSA isolates were susceptible to vancomycin and trimethoprimsulfamethoxazole. Few patients who received clindamycin were resistant to clindamycin (3.9% [2/51]). No patients died in the hospital. There were no significant differences between the vancomycin (n = 40) and clindamycin (n = 51) groups with respect to composite failure (15.0% [6/40] vs 7.8% [4/51], respectively), microbiologic failure (2.5% [1/40] vs 3.9% [2/51]), additional inpatient interventions (5.0% [2/40] vs 3.9% [2/51]), or additional outpatient interventions (12.5% [5/40] vs 3.9% [2/51]). Most patients (93.4% [85/91]) received incision and drainage. When those who did not were excluded from the analyses, all trends remained unchanged. Conclusions: In a single institution with a low rate of clindamycin resistance, there were no significant differences between vancomycin and clindamycin for the treatment of these hospitalized patients with MRSA skin infections, on the basis of clinical outcomes data. This finding warrants further investigation in a randomized controlled trial." @default.
• W2113257039 created "2016-06-24" @default.
• W2113257039 creator A5002862479 @default.
• W2113257039 creator A5006574883 @default.
• W2113257039 creator A5035224173 @default.
• W2113257039 creator A5057165734 @default.
• W2113257039 creator A5061941277 @default.
• W2113257039 creator A5072887608 @default.
• W2113257039 date "2010-11-01" @default.
• W2113257039 modified "2023-10-16" @default.
• W2113257039 title "Retrospective cohort study of hospitalized adults treated with vancomycin or clindamycin for methicillin-resistant Staphylococcus aureus skin infections" @default.
• W2113257039 cites W1973548296 @default.
• W2113257039 cites W1993812164 @default.
• W2113257039 cites W2020188983 @default.
• W2113257039 cites W2025854263 @default.
• W2113257039 cites W2030539985 @default.
• W2113257039 cites W2053720086 @default.
• W2113257039 cites W2056026648 @default.
• W2113257039 cites W2073299368 @default.
• W2113257039 cites W2076055319 @default.
• W2113257039 cites W2114114837 @default.
• W2113257039 cites W2114899304 @default.
• W2113257039 cites W2115362037 @default.
• W2113257039 cites W2125675160 @default.
• W2113257039 cites W2131316809 @default.
• W2113257039 cites W2135161828 @default.
• W2113257039 cites W2138738218 @default.
• W2113257039 cites W2146199418 @default.
• W2113257039 cites W2152694096 @default.
• W2113257039 cites W2158214597 @default.
• W2113257039 cites W2168836899 @default.
• W2113257039 cites W2268708037 @default.
• W2113257039 cites W2318646163 @default.
• W2113257039 doi "https://doi.org/10.1016/j.clinthera.2010.11.004" @default.
• W2113257039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21118737" @default.
• W2113257039 hasPublicationYear "2010" @default.
• W2113257039 type Work @default.
• W2113257039 sameAs 2113257039 @default.
• W2113257039 citedByCount "7" @default.
• W2113257039 countsByYear W21132570392012 @default.
• W2113257039 countsByYear W21132570392013 @default.
• W2113257039 countsByYear W21132570392016 @default.
• W2113257039 crossrefType "journal-article" @default.
• W2113257039 hasAuthorship W2113257039A5002862479 @default.
• W2113257039 hasAuthorship W2113257039A5006574883 @default.
• W2113257039 hasAuthorship W2113257039A5035224173 @default.
• W2113257039 hasAuthorship W2113257039A5057165734 @default.
• W2113257039 hasAuthorship W2113257039A5061941277 @default.
• W2113257039 hasAuthorship W2113257039A5072887608 @default.
• W2113257039 hasConcept C126322002 @default.
• W2113257039 hasConcept C141071460 @default.
• W2113257039 hasConcept C167135981 @default.
• W2113257039 hasConcept C2777052132 @default.
• W2113257039 hasConcept C2777334864 @default.
• W2113257039 hasConcept C2777458120 @default.
• W2113257039 hasConcept C2778980435 @default.
• W2113257039 hasConcept C2779489039 @default.
• W2113257039 hasConcept C501593827 @default.
• W2113257039 hasConcept C523546767 @default.
• W2113257039 hasConcept C54355233 @default.
• W2113257039 hasConcept C71924100 @default.
• W2113257039 hasConcept C86803240 @default.
• W2113257039 hasConcept C89423630 @default.
• W2113257039 hasConceptScore W2113257039C126322002 @default.
• W2113257039 hasConceptScore W2113257039C141071460 @default.
• W2113257039 hasConceptScore W2113257039C167135981 @default.
• W2113257039 hasConceptScore W2113257039C2777052132 @default.
• W2113257039 hasConceptScore W2113257039C2777334864 @default.
• W2113257039 hasConceptScore W2113257039C2777458120 @default.
• W2113257039 hasConceptScore W2113257039C2778980435 @default.
• W2113257039 hasConceptScore W2113257039C2779489039 @default.
• W2113257039 hasConceptScore W2113257039C501593827 @default.
• W2113257039 hasConceptScore W2113257039C523546767 @default.
• W2113257039 hasConceptScore W2113257039C54355233 @default.
• W2113257039 hasConceptScore W2113257039C71924100 @default.
• W2113257039 hasConceptScore W2113257039C86803240 @default.
• W2113257039 hasConceptScore W2113257039C89423630 @default.
• W2113257039 hasIssue "12" @default.
• W2113257039 hasLocation W21132570391 @default.
• W2113257039 hasLocation W21132570392 @default.
• W2113257039 hasOpenAccess W2113257039 @default.
• W2113257039 hasPrimaryLocation W21132570391 @default.
• W2113257039 hasRelatedWork W1530437508 @default.
• W2113257039 hasRelatedWork W1883268623 @default.
• W2113257039 hasRelatedWork W1995533152 @default.
• W2113257039 hasRelatedWork W1997788533 @default.
• W2113257039 hasRelatedWork W2108483943 @default.
• W2113257039 hasRelatedWork W2110928570 @default.
• W2113257039 hasRelatedWork W2126874046 @default.
• W2113257039 hasRelatedWork W2140683589 @default.
• W2113257039 hasRelatedWork W2532901088 @default.
• W2113257039 hasRelatedWork W3028811422 @default.
• W2113257039 hasVolume "32" @default.
• W2113257039 isParatext "false" @default.
• W2113257039 isRetracted "false" @default.
• W2113257039 magId "2113257039" @default.
• W2113257039 workType "article" @default.